To begin investigating the function of GPS2 as a tumor suppressor in triple negative breast cancer, we generated two MDA-MB-231-GPS2 knockout lines by CRISPR-Cas9 genome editing with two independent sets of sgRNA (Supplementary Figure 1A). This evidence concerns the gene GPS2 and triple-negative breast carcinoma.